Related Experiment Video
Updated: Jan 26, 2026

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
Published on: April 28, 2020
Platelet Factor 4 Attenuates Experimental Acute Liver Injury in Mice
Hannah K Drescher1, Elisa F Brandt1, Petra Fischer1
1Department of Internal Medicine III, University Hospital, RWTH Aachen, Aachen, Germany.
Abstract:
Platelet factor 4 (PF4) is a pleiotropic inflammatory chemokine, which has been implicated in various inflammatory disorders including liver fibrosis. However, its role in acute liver diseases has not yet been elucidated. Here we describe an unexpected, anti-inflammatory role of PF4. Serum concentrations of PF4 were measured in patients and mice with acute liver diseases. Acute liver injury in mice was induced either by carbon tetrachloride or by D-galactosamine hydrochloride and lipopolysaccharide. Serum levels of PF4 were decreased in patients and mice with acute liver diseases. PF4 mice displayed increased liver damage in both models compared to control which was associated with increased apoptosis of hepatocytes and an enhanced pro-inflammatory response of liver macrophages. In this experimental setting, PF4 mice were unable to generate activated Protein C (APC), a protein with anti-inflammatory activities on monocytes/macrophages. In vitro, PF4 limited the activation of liver resident macrophages. Hence, the systemic application of PF4 led to a strong amelioration of experimental liver injury. Along with reduced liver injury, PF4 improved the severity of the pro-inflammatory response of liver macrophages and induced increased levels of APC. PF4 has a yet unidentified direct anti-inflammatory effect in two models of acute liver injury. Thus, attenuation of acute liver injury by systemic administration of PF4 might offer a novel therapeutic approach for acute liver diseases.
Insights
Platelet factor 4 (PF4) unexpectedly shows anti-inflammatory effects in acute liver injury. Lower PF4 levels worsen liver damage, while PF4 administration protects against liver disease.
Area of Science:
- Immunology
- Hepatology
- Inflammation research
Background:
- Platelet factor 4 (PF4) is known for inflammatory roles in liver fibrosis.
- Its function in acute liver diseases remains unclear.
Purpose of the Study:
- To investigate the role of PF4 in acute liver injury.
- To explore PF4's potential as a therapeutic agent for acute liver diseases.
Main Methods:
- Measured serum PF4 levels in patients and mice with acute liver diseases.
- Induced acute liver injury in mice using carbon tetrachloride or D-galactosamine/lipopolysaccharide.
- Utilized PF4 knockout mice to assess PF4's protective or detrimental effects.
- Administered PF4 systemically to evaluate its therapeutic potential.
- Conducted in vitro studies on liver macrophages.
Main Results:
- Serum PF4 levels were decreased in patients and mice with acute liver diseases.
- PF4 knockout mice exhibited exacerbated liver damage, increased hepatocyte apoptosis, and heightened pro-inflammatory macrophage responses.
- PF4 knockout mice showed impaired generation of anti-inflammatory Protein C (APC).
- In vitro, PF4 limited liver resident macrophage activation.
- Systemic PF4 administration ameliorated experimental liver injury, reduced macrophage inflammation, and increased APC levels.
Conclusions:
- PF4 exhibits a previously unrecognized anti-inflammatory role in acute liver injury.
- Reduced PF4 levels contribute to increased liver damage and inflammation.
- Systemic PF4 administration demonstrates therapeutic potential for acute liver diseases.
Related Concept Videos
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...

